Payment overview · 2025
General Payments
$2,957.03
112 reported records · 18 companies
Healthcare provider profile · identity verified
Meril S Platzer, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · WOODLAND HILLS, CA · NPI 1215963939
Verified facts
What the public records show
CMS Open Payments records show Meril S Platzer, M.D. received $2,957.03 in general payments during 2025 across 112 reported records.
ABBVIE INC. accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Hizentra, Ingrezza.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Hizentra as an associated drug or biological on 13634 records involving 4691 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Hizentra by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ingrezza by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $752.70 | 25.4% | 21 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$517.68 | 17.5% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $356.91 | 12.1% | 36 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $306.66 | 10.4% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $270.84 | 9.2% | 6 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $206.58 | 7.0% | 13 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$170.71 | 5.8% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.28 | 2.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $60.70 | 2.0% | 3 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.68 | 1.5% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $30.35 | 1.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.44 | 1.0% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $28.05 | 0.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.40 | 0.9% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $23.75 | 0.8% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $23.50 | 0.8% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $22.88 | 0.8% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $21.92 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,957.03 | 112 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $511.05 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $356.91 | 36 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $356.91 | 36 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $306.66 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $270.84 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $241.65 | 9 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $241.24 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $206.58 | 13 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $170.71 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $133.30 | 9 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $65.28 | 3 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $60.70 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $43.68 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $30.35 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $28.44 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $28.05 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $26.40 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $21.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Hizentra hizentra |
2025 | Hizentra | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Hizentra open payments reported associated product |
CMS Open Payments — General Payments 13634 supporting records · 4691 recipient NPIs · example record 1232339012 |
Hizentra · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 181 | 43 |
| Memantine Hcl | Memantine Hcl | 181 | 42 |
| Donepezil Hcl | Donepezil Hcl | 144 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 28 |
| Buspirone Hcl | Buspirone Hcl | 92 | 17 |
| Lorazepam | Lorazepam | 90 | 17 |
| Alprazolam | Alprazolam | 84 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 13 |
| Baclofen | Baclofen | 77 | 15 |
| Clonazepam | Clonazepam | 72 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 64 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | 12 |
| Lacosamide | Lacosamide | 58 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 57 | 12 |
| Sertraline Hcl | Sertraline Hcl | 57 | 15 |
| Trazodone Hcl | Trazodone Hcl | 50 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 49 | 13 |
| Bupropion Hcl | Bupropion Hcl | 47 | 13 |
| Pregabalin | Pregabalin | 45 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 15 |
| Temazepam | Temazepam | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 28 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Lamictal Xr | Lamotrigine | 26 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 26 | suppressed |
| Amantadine | Amantadine Hcl | 25 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 19 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 15 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 13 | suppressed |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Tegretol Xr | Carbamazepine | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,957.03 · 112 records | ABBVIE INC. | AUSTEDO XR, Gocovri, Hizentra, INGREZZA, KISUNLA, Leqembi, NURTEC ODT, Ocrevus Zunovo, QULIPTA, Qelbree, REXULTI, Sunosi, UBRELVY, VALTOCO, VRAYLAR, VUMERITY, VYVGART HYTRULO, WaveWriter Alpha Prime 16, XCOPRI, ZAVZPRET, ZTLido | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Hizentra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with CSL Behring?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error